Back to results
US 12,351,831 B2Granted
Platform for the induction and maintenance of ground state pluripotency
AssigneeFate Therapeutics, Inc.
InventorsBahram Valamehr, Megan Robinson, Ramzey Abujarour
Life of this patent
Estimating the term…
Abstract
The invention provides compositions and methods for manufacturing pluripotent cells. In particular, the invention provides improved culture platforms for manufacturing pluripotent cells with ground state pluripotency.
Claims20
A composition for reprogramming human non-pluripotent cells to pluripotent cells, the composition comprising one or more exogenous polynucleotides encoding a plurality of polypeptides, wherein the plurality of polypeptides comprises:
- (i) a first combination comprising octamer-binding transcription factor 4 (OCT4) and one or more polypeptides selected from the group consisting of sex determining region Y-Box-2 (SOX2), NANOG, Kruppel-like factor (KLF), LIN28, cellular MYC (C-MYC), ES cell associated transcript 1 (ECAT1), Undifferentiated Embryonic Cell Transcription Factor 1 (UTF1), Estrogen Related Receptor Beta (ESRRB), and Simian virus 40 large T antigen (SV40LT);
- and
- (ii) a second combination comprising:
- (a) hES cells related gene (HESRG), Cadherin 1 (CDH1), and Zinc finger of the cerebellum protein family member 3 (ZIC3);
- or
- (b) teratocarcinoma-derived growth factor 1 (TDGF1), Developmental Pluripotency Associated 4 (DPPA4), and LINE-1 type transposase domain-containing protein 1 (LITD1).
3 more elements
Dependencies are inferred from the claim text.